A Phase III, Randomized, Double-Blind, Placebo- and Active-controlled Study of SHR8554 Injection for the Treatment of Pain After Abdominal Surgery
Latest Information Update: 08 Jul 2022
At a glance
- Drugs Tegileridine (Primary) ; Morphine
- Indications Postoperative pain
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 04 Jul 2022 Status changed from recruiting to completed.
- 22 Aug 2021 Planned number of patients changed from 192 to 528.
- 22 Aug 2021 Planned End Date changed from 31 Jul 2021 to 30 Dec 2021.